<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498509</url>
  </required_header>
  <id_info>
    <org_study_id>153PAR14017</org_study_id>
    <nct_id>NCT02498509</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-342</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Active-controlled, Multicenter phase 3 Clinical trial to evaluate
      the Efficacy and Safety of Concomitant Mometasone furoate and Levocabastine HCl in Perennial
      Allergic Rhinitis patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in rTNSS from baseline</measure>
    <time_frame>up to week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in rTNSS from baseline</measure>
    <time_frame>up to week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AM rTNSS and PM rTNSS from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the baseline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician assessed overall nasal symptom from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the basline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in RQLQ</measure>
    <time_frame>2 weeks and 4 weeks after the baseline assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in 4 nasal symptom score (sneezing, runny nose, nasal congestion, itchy nose) from baseline</measure>
    <time_frame>2 weeks and 4 weeks after the basline assessment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">459</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-342</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mometasone furoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levocabastine HCL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-342</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Control 1</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocabastine HCL</intervention_name>
    <description>treatment for 4 weeks after randomization</description>
    <arm_group_label>Control 2</arm_group_label>
    <other_name>investigational product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male, female, Age: over 13 years(no age limiation in upper)

          2. subject who has experienced perennial allergic rhinitis for over 1 year

          3. subject who has identified allergens throughout the year within 12 months

          4. subject who has the symptoms of moderate to severe allergic rhinitis

          5. subject who can record the the patient diary during the clinical trial period

          6. subject who agreed to keep the same environment during the clinical trial period

        Exclusion Criteria:

          1. Asthma

          2. Previous medical history at screening (Nasal polyps within the previous two months,
             biopsies, ulcers, trauma, surgery, atrophic rhinitis, patients with a history of drug
             rhinitis)

          3. Patients with untreated localized infection in nasal mucosa

          4. Patients following administration of a combination of prohibited drugs in patients
             administered concomitant medications or trial period is expected to be inevitable

          5. Patients with abnormal following laboratory test results at screening

               -  AST, ALT&gt;2times the upper limit of normal at screening

               -  Serum creatinine &gt;1.5times the upper limit of normal at screening

          6. Previous history of acute or severe chronic sinusitis within 30 days at screening

          7. The continue use of drugs that may affect the efficacy of the Investigational product

          8. Start the immunotherapy or a change of doge within 1 month, at screening

          9. If you have glaucoma or cataracts, herpes simplex, or around the eyes

         10. Chronic obstructive pulmonary disease (COPD)

         11. history of hypersensitivity reactions and for treaties or major components of the IP

         12. Pregnant women, breast feeding women or women of childbearing potential must agree to
             use appropriate contraception methods

         13. Alcohol or illegal drug abuse or dependence in patients

         14. participation in any investigational or maketed drug within 4weeks preceding the
             screening visit

         15. Patients that can not be participating in a clinical trial by investigator's
             discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Irwon-dong</city>
        <state>Gangnam-gu, Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Levocabastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

